Transgene Biotek Ltd

Transgene Biotek Limited informed the BSE Limited that M/s. Eswara Rao & Co., Chartered Accountants (Firm Registration No. 000816S), resigned as the company's statutory auditors with effect from October 28, 2026, citing pre-occupation with other assignments and an inability to devote sufficient time to the company's affairs. The resignation followed the auditors' appointment on October 10, 2026, to fill a casual vacancy previously held by M/s. Vasavi & Co., Chartered Accountants, and they confirmed they did not commence any audit or limited review work prior to their resignation.

Transgene Biotek Limited announced that M/s. Eswara Rao & Co., Chartered Accountants, have resigned as the company’s statutory auditors with immediate effect, citing pre-occupation with other assignments, according to a regulatory filing on October 29, 2026. The resignation was tendered in a letter dated October 28, 2026, and the company will take steps to appoint a new statutory auditor in accordance with applicable regulations.

Transgene Biotek Limited informed the Bombay Stock Exchange that the Statement of Deviation or Variation under Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is not applicable for the quarter ended September 30, 2026, due to the absence of a public issue, rights’ issue, or preferential issue during that period.

Transgene Biotek Limited informed the BSE Limited that the company has not issued any Non-Convertible Securities, rendering Regulation 57(5) of the SEBI (LODR) Regulations, 2015 not applicable for the quarter ended September 30, 2026.

Transgene Biotek Limited informed the BSE Limited that Regulation 57 of SEBI’s (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company for the quarter ended September 30, 2026, as there are no non-convertible securities for which interest, dividend, or principal is payable.

Transgene Biotek Limited confirmed it does not meet the criteria to be classified as a “Large Corporate” under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, and BSE Circular No. LIST/COM/05/2019 -20 dated April 11, 2019, in a filing with the BSE Limited on October 3, 2026.

Transgene Biotek confirmed compliance with Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, stating that its Registrar and Share Transfer Agent, Bigshare Services Private Limited, a SEBI-registered Category-I agent with registration number INR000001385, maintains both physical and electronic share transfer facilities.

Transgene Biotek Limited submitted a confirmation certificate dated October 3, 2026, to the BSE Limited regarding the dematerialization and rematerialization of shares through National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) from July 1, 2026, to September 30, 2026, as per Regulation 74(5) of the SEBI (Depositories & Participants) Regulations, 2018, with Bigshare Services Private Limited acting as the Registrar and Share Transfer Agent.

Transgene Biotek Limited will hold a board meeting on Saturday, October 10, 2026, to consider the appointment of M/s. Eswara Rao & Co., Chartered Accountants, as the company’s statutory auditors, succeeding M/s. Vasavi & Co., Chartered Accountants, subject to audit committee recommendation and member approval.

Transgene Biotek Limited informed the BSE Limited that the trading window for dealing in securities of the company will be closed for all Directors, Key Managerial Personnel, Designated Employees, and Connected Persons from October 1, 2026, until 48 hours after the declaration of the company’s Limited reviewed Financial Results for the second quarter ending September 30, 2026.